Search research articles
Contact Us
Filters
Showing results (21-30 of 30) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 30 results.
Mammalian Genome : Official Journal of the International Mammalian Genome Society
|
December 14, 1999
Alternative splicing, gene localization, and binding of SH2-B to the insulin receptor kinase domain
K Nelms, T J O'Neill, S Li, et al.
Science (New York, N.Y.)
|
December 20, 1991
Identification and characterization of zinc binding sites in protein kinase C
S R Hubbard, W R Bishop, P Kirschmeier, et al.
Nature Structural Biology
|
January 3, 2001
Mechanism-based design of a protein kinase inhibitor
K Parang, J H Till, A J Ablooglu, et al.
The Journal of Biological Chemistry
|
January 2, 2001
Crystallographic and solution studies of an activation loop mutant of the insulin receptor tyrosine kinase: insights into kinase mechanism
J H Till, A J Ablooglu, M Frankel, et al.
Science (New York, N.Y.)
|
May 9, 1997
Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors
M Mohammadi, G McMahon, L Sun, et al.
The Journal of Biological Chemistry
|
June 28, 2000
Probing the catalytic mechanism of the insulin receptor kinase with a tetrafluorotyrosine-containing peptide substrate
A J Ablooglu, J H Till, K Kim, et al.
Nature
|
February 9, 1995
Catalytic specificity of protein-tyrosine kinases is critical for selective signalling
Z Songyang, K L Carraway, M J Eck, et al.
The EMBO Journal
|
October 17, 1998
Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain
M Mohammadi, S Froum, J M Hamby, et al.
Pediatrics
|
January 31, 1998
Mutation screening of the BTK gene in 56 families with X-linked agammaglobulinemia (XLA): 47 unique mutations without correlation to clinical course
E Holinski-Feder, M Weiss, O Brandau, et al.
Cancer Research
|
August 17, 2000
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
A D Laird, P Vajkoczy, L K Shawver, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 30) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 30 results.
Mammalian Genome : Official Journal of the International Mammalian Genome Society
|
December 14, 1999
Alternative splicing, gene localization, and binding of SH2-B to the insulin receptor kinase domain
K Nelms, T J O'Neill, S Li, et al.
Science (New York, N.Y.)
|
December 20, 1991
Identification and characterization of zinc binding sites in protein kinase C
S R Hubbard, W R Bishop, P Kirschmeier, et al.
Nature Structural Biology
|
January 3, 2001
Mechanism-based design of a protein kinase inhibitor
K Parang, J H Till, A J Ablooglu, et al.
The Journal of Biological Chemistry
|
January 2, 2001
Crystallographic and solution studies of an activation loop mutant of the insulin receptor tyrosine kinase: insights into kinase mechanism
J H Till, A J Ablooglu, M Frankel, et al.
Science (New York, N.Y.)
|
May 9, 1997
Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors
M Mohammadi, G McMahon, L Sun, et al.
The Journal of Biological Chemistry
|
June 28, 2000
Probing the catalytic mechanism of the insulin receptor kinase with a tetrafluorotyrosine-containing peptide substrate
A J Ablooglu, J H Till, K Kim, et al.
Nature
|
February 9, 1995
Catalytic specificity of protein-tyrosine kinases is critical for selective signalling
Z Songyang, K L Carraway, M J Eck, et al.
The EMBO Journal
|
October 17, 1998
Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain
M Mohammadi, S Froum, J M Hamby, et al.
Pediatrics
|
January 31, 1998
Mutation screening of the BTK gene in 56 families with X-linked agammaglobulinemia (XLA): 47 unique mutations without correlation to clinical course
E Holinski-Feder, M Weiss, O Brandau, et al.
Cancer Research
|
August 17, 2000
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
A D Laird, P Vajkoczy, L K Shawver, et al.
Page
of 3